A record number of over 270 innovators from academia and industry came together in Munich for this year’s BioVaria, one of Europe’s leading events boosting partnerships for the transfer of life-science inventions into application.

Gramibactin is an iron-binding molecule of the siderophore family. It occurs naturally in certain plant-associated bacteria where it helps secure the…

Ascenion GmbH, the technology transfer partner of the Helmholtz Centre for Infection Research (HZI), has supported the negotiations for a licence…

Technology sneak peek from Ascenion: Seven breakthrough life-science inventions                                      

12 March 2019, Munich, Germany…

Ascenion GmbH, the technology transfer partner of the Helmholtz Centre for Infection Research (HZI), has supported the negotiations for a…

BioVaria is organised by Ascenion and several other technology transfer organisations from all across Europe. The conference brings together Europe’s…

Ascenion Negotiated Additional Licence Agreement between Helmholtz Zentrum München and Medigene

9 January 2019, Munich – The Helmholtz Zentrum…

Agreement with Max Delbrück Center Provides Access to Broad Intellectual Property Portfolio of Unique Humanized Antibody Fragments and Antigen-Binding…

Don’t miss your chance to secure a spot at next year’s BioVaria, 8 - 9 May 2019 in Munich! Application for European startups is now open until 1^st…

Following the successful completion of a Phase I trial with its cardioprotective lead candidate OMT-28, OMEICOS has now closed a Series C financing…

iThera Medical, a spin-off from the Helmholtz Zentrum München, has closed series C financing with new investors FLUXUNIT, the corporate venture…

Amgen announced that the Japanese Ministry of Health, Labour and Welfare has granted marketing approval for BLINCYTO® (blinatumomab) for the treatment…

Shire’s VEYVONDI received EU market authorization for the treatment of bleeding events and the prevention or treatment of surgical bleeding in…

The European Commission has granted approval for Amgen’s BLINCYTO® (blinatumomab) for the treatment of pediatric patients with certain forms of B cell…

Drug developer Berlin Cures announced the successful completion of its Phase 1 study of its lead candidate BC 007 for the treatment of cardiomyopathy.…

Ascenion’s portfolio company OMEICOS reported positive Phase I data for its lead candidate OMT-28, a small molecule with strong anti-arrhythmic and…

Phase I study initiated with candidate against multidrug-resistant germs 

6 June 2018, Munich – The Leibniz Institute for Natural Product Research…

Technology sneak peek from Ascenion: Five breakthrough life-science inventions

9 March 2018, Munich, Germany – On 23–24 April 2018, decision makers…

BioVaria brings together Europe’s top scientists and technology transfer professionals with potential licensees and investors from the international…

BioVaria Spin-off Awards go to Captain T Cell and Provirex

24 May 2017, Munich, Germany – On 22–23 May 2017, over 180 innovative minds gathered in…

Join Europe’s leading showcase for life-science inventions!

Ascenion is proud to present a strong line-up of speakers, participants and technologies…

Technology Sneak Peek from Ascenion: Human T-cell receptors for cancer therapy

4 April 2017, Munich, Germany – On 22-23 May 2017, dealmakers from…

This January, the UTILE project was launched under the European H2020 Research and Innovation Program. It is designed to help commercialize the…

This year’s BioVaria Anniversary Edition will, for the first time, extend over two days and include the promising field of digital health. Top-tier…

During the last weeks, a team of Ascenion’s industry liaison and technology mangers has been on the road to foster industry relations and market the…

Around 40 commercially attractive, licensable technologies that were presented at this year’s BioVaria are now available online – including videos of…

BioVaria Spin-off Awards go to Charité spin-off and Braingineering Technologies

19 May 2016, Munich, Germany – Dealmakers and investors from the…

Join Europe’s leading market place for life-science inventions!

Ascenion unveils technology highlights: New approaches for the treatment of neurodegenerative disorders and glioblastoma

BioVaria is designed for dealmakers and investors from the global life-science sector responsible for identifying, licensing or funding break-through…